Related Experiment Video
Updated: May 13, 2026
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Pioglitazone--do we really need it to manage type 2 diabetes?
1AMRI Hospitals, Salt Lake, Kolkata, India. binayaksinha@rediffmail.com
Diabetes & Metabolic Syndrome
|March 23, 2013
Summary
Newer diabetes medications offer improved safety and efficacy compared to older controversial drugs like pioglitazone. This review examines the benefits and risks of pioglitazone versus newer agents such as DPP-4 inhibitors and SGLT-2 inhibitors.
Area of Science:
- Endocrinology
- Pharmacology
- Diabetology
Background:
- Several important diabetes medications have been withdrawn from the market due to safety concerns.
- Pioglitazone, a thiazolidinedione, improves insulin sensitivity but faces controversies including weight gain, fractures, and bladder cancer risks.
- Newer drug classes like DPP-4 inhibitors, GLP-1 analogues, bromocriptine, and SGLT-2 inhibitors have emerged with stringent FDA approval.
Purpose of the Study:
- To critically evaluate the controversial drug pioglitazone in light of newly available therapeutic options.
- To compare the metabolic and extra-glycemic benefits of pioglitazone against newer antidiabetic agents.
- To address the clinical need for pioglitazone given the availability of agents with potentially better safety profiles.
Main Methods:
- Literature review and critical analysis of existing studies on pioglitazone and newer antidiabetic drug classes.
- Comparative assessment of efficacy, safety profiles, and side effects.
- Evaluation of glycemic control, hypoglycemia risk, and weight changes associated with different drug classes.
Main Results:
- Newer agents demonstrate significant glucose-lowering effects with favorable side effect profiles, particularly regarding hypoglycemia and weight gain.
- Pioglitazone, despite its insulin-sensitizing and potential cardioprotective effects, carries significant risks including weight gain, fractures, and potential bladder cancer.
- The emergence of DPP-4 inhibitors, GLP-1 analogues, and SGLT-2 inhibitors offers alternatives with improved safety and metabolic benefits.
Conclusions:
- The availability of newer antidiabetic agents with better safety and metabolic profiles questions the continued necessity of controversial drugs like pioglitazone.
- A thorough risk-benefit analysis favors newer agents over pioglitazone for managing type 2 diabetes.
- Future research should continue to monitor the long-term safety and efficacy of all available antidiabetic medications.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...